Turmoil In Allergy Market Continues As Merck Ends ALK Partnership

27 Jul 2016

• By John Davis

Merck & Co has returned all US marketing rights to ALK-Abello’s sublingual allergy tablets to the Danish company, casting a pall over the sector that has this year been dismayed by late-stage failures of new products and delays in drug development.

Developing the market for new allergy vaccines is proving difficult and has claimed another casualty, the US marketing partnership between Merck & Co. Inc. and Denmark’s ALK-Abello A/S, with the US Big Pharma returning all rights to ALK’s sublingual allergy immunotherapy tablets (SLIT) in North America.

The discontinuation followed a review of Merck’s strategic priorities and, after a six-month transition period, the rights to the SLIT...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Apellis’ Empaveli Expansion Underway In Rare Kidney Disease

29 Jul 2025

• By Jessica Merrill

The US FDA approved the complement C3 inhibitor for new indications in C3G and primary IC-MPGN, providing a new growth opportunity for Apellis.

CEO Underlines AstraZeneca’s Increasingly US-Centric Growth Plans

29 Jul 2025

• By Andrew McConaghie

Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.